Paper389478
Podophyllotoxin derivative VP 16-213.
Arnold AM. Cancer Chemother Pharmacol, 1979. Cited by 92 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Podophyllotoxin derivative VP 16-213. Papers, record 389478. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/389478
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Etoposide | Major topic |
| Neoplasms | Major topic |
| Podophyllotoxin | Major topic |
| Animals | |
| Bronchial Neoplasms | |
| Carcinoma | |
| Clinical Trials as Topic | |
| Drug Administration Schedule | |
| Drug Evaluation | |
| Drug Therapy, Combination | |
| Humans | |
| In Vitro Techniques | |
| Leukemia, Monocytic, Acute | |
| Leukemia, Myeloid | |
| Lymphoma | |
| Mice | |
| Rabbits | |
| Rats | |
| Sarcoma |
Source PubMed
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 679,171 | Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. | Cancer Res | 1978 | https://conductscience.org/library/papers/679171 | PubMed |
| 2 | 688,275 | Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells. | Cancer Treat Rep | 1978 | https://conductscience.org/library/papers/688275 | PubMed |
| 3 | 4,855,812 | Interaction of drugs with microtubule proteins. | Fed Proc | 1974 | https://conductscience.org/library/papers/4855812 | PubMed |
| 4 | 1,157,447 | PTG, a new antineoplastic epipodyphyllotoxin. | Clin Pharmacol Ther | 1975 | https://conductscience.org/library/papers/1157447 | PubMed |
| 5 | 4,634,038 | Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213). | Cancer Chemother Rep | 1972 | https://conductscience.org/library/papers/4634038 | PubMed |
| 6 | 4,578,134 | Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours. | Br Med J | 1973 | https://conductscience.org/library/papers/4578134 | PubMed |
| 7 | 657,164 | Evaluation of VP-16-213 in malignant lymphoma and melanoma. | Cancer Treat Rep | 1978 | https://conductscience.org/library/papers/657164 | PubMed |
| 8 | 1,016,966 | Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213. | Cancer Treat Rep | 1976 | https://conductscience.org/library/papers/1016966 | PubMed |
| 9 | 939,236 | Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia. | Eur J Cancer (1965) | 1976 | https://conductscience.org/library/papers/939236 | PubMed |
| 10 | 999,819 | Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. | Biochemistry | 1976 | https://conductscience.org/library/papers/999819 | PubMed |
| 11 | 1,203,893 | Myocardial infarction in a 27-year-old woman: possible complication of treatemtn with VP-16-213 (NSC-141540), mediastinal irradiation, or both. | Cancer Chemother Rep | 1975 | https://conductscience.org/library/papers/1203893 | PubMed |
| 12 | 1,036,468 | Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer. | Cancer Treat Rep | 1976 | https://conductscience.org/library/papers/1036468 | PubMed |
| 13 | 1,009,527 | PHASE I clinical trial of an oral solution of VP-16-213. | Cancer Treat Rep | 1976 | https://conductscience.org/library/papers/1009527 | PubMed |
| 15 | 1,204,664 | Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives. | Eur J Cancer (1965) | 1975 | https://conductscience.org/library/papers/1204664 | PubMed |
| 16 | 348,319 | VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. | Cancer Treat Rep | 1978 | https://conductscience.org/library/papers/348319 | PubMed |
| 17 | 657,168 | VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. | Cancer Treat Rep | 1978 | https://conductscience.org/library/papers/657168 | PubMed |
| 18 | 976,288 | Antimetastasis effect of two derivatives of epiposophyllotoxin in mice. | Eur J Cancer (1965) | 1976 | https://conductscience.org/library/papers/976288 | PubMed |
| 19 | 4,991,932 | 4'-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action. | Eur J Cancer (1965) | 1970 | https://conductscience.org/library/papers/4991932 | PubMed |
| 20 | 194,694 | Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma. | Cancer Treat Rep | 1977 | https://conductscience.org/library/papers/194694 | PubMed |
| 21 | 4,760,528 | Effects of a new antitumor agent, epipodophyllotoxin, on growth and chromosomes in human hematopoietic cell lines. | Cancer Res | 1973 | https://conductscience.org/library/papers/4760528 | PubMed |
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 92 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 26,464,822 | 6-Methoxy Podophyllotoxin Induces Apoptosis via Inhibition of TUBB3 and TOPIIA Gene Expressions in 5637 and K562 Cancer Cell Lines. | Cell J | 2015 | https://conductscience.org/library/papers/26464822 | PubMed |
| 23,849,350 | Preparation of hierarchical mesoporous CaCO3 by a facile binary solvent approach as anticancer drug carrier for etoposide. | Nanoscale Res Lett | 2013 | https://conductscience.org/library/papers/23849350 | PubMed |
| 15,139,794 | Pharmacokinetic optimisation of treatment with oral etoposide. | Clin Pharmacokinet | 2004 | https://conductscience.org/library/papers/15139794 | PubMed |
| 7,497,580 | Stability of the i.v. and oral formulations of etoposide in solution. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7497580 | PubMed |
| 7,236,488 | Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7236488 | PubMed |
| 7,083,459 | Etoposide as a single agent in relapsed advanced lymphomas. A phase II study. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083459 | PubMed |
| 7,083,454 | Pharmacokinetics of VP16-213 given by different administration methods. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083454 | PubMed |
| 7,083,452 | Interaction of VP16-213 with the DNA repair antagonist chloroquine. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083452 | PubMed |
| 7,044,596 | Current development of podophyllotoxins. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044596 | PubMed |
| 7,044,594 | VP16-213 (etoposide). A critical review of its activity. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044594 | PubMed |
| 7,044,592 | The clinical pharmacology of VM26 and VP16-213. A brief overview. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044592 | PubMed |
| 7,044,591 | VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044591 | PubMed |
| 7,031,350 | [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)]. | Klin Wochenschr | 1981 | https://conductscience.org/library/papers/7031350 | PubMed |
| 6,861,265 | Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma. | Cancer Chemother Pharmacol | 1983 | https://conductscience.org/library/papers/6861265 | PubMed |
| 6,690,078 | Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer. | Cancer Chemother Pharmacol | 1984 | https://conductscience.org/library/papers/6690078 | PubMed |
| 6,481,426 | Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. | J Neurooncol | 1984 | https://conductscience.org/library/papers/6481426 | PubMed |
| 6,282,480 | Epipodophyllotoxin (VP16-213) in small cell carcinoma of the Bronchus resistant to initial combination chemotherapy. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/6282480 | PubMed |
| 3,555,940 | Pharmacokinetics of anticancer drugs in children. | Clin Pharmacokinet | 1987 | https://conductscience.org/library/papers/3555940 | PubMed |
| 3,410,665 | Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group. | Invest New Drugs | 1988 | https://conductscience.org/library/papers/3410665 | PubMed |
| 3,297,462 | The clinical pharmacology of etoposide and teniposide. | Clin Pharmacokinet | 1987 | https://conductscience.org/library/papers/3297462 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/389478
GET https://conductscience.org/api/papers/v1/389478/references?page=2